Liminatus Pharma, Inc.
LIMN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $105.1K in total; no superinvestor holds it.
Other share classesLIMNW
Q3 2025 vs. Q2 2025
How the institutions holding Liminatus Pharma, Inc. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 10 | 10 | 0 |
| Shares | 204.7K | 261.9K | +57.2K (+28.0%) |
| Value | $2.28M | $437.4K | −$1.84M (−80.8%) |
New holders (3)
Institutions that held Liminatus Pharma, Inc. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jane Street Group, LLC | 39,635 | $66.2K | 0.00% |
| Squarepoint Ops LLC | 10,403 | $17.4K | 0.00% |
| Farther Finance Advisors, LLC | 31 | $52 | 0.00% |
Sold out (3)
Institutions that held Liminatus Pharma, Inc. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| Royal Bank of Canada | 2,886 | $32.0K |
| Barclays PLC | 184 | $2.05K |
| SBI Securities Co., Ltd. | 52 | $580 |